PRNewsWire
15 Nov 2026, 17:05 UTC · 1d ago
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
Impact · against what's priced in
Viking Therapeutics sees a positive catalyst from new exploratory data showing a 74% BMI category improvement rate and broad cardiometabolic benefits. While the raw weight loss percentages were already known, the depth of these metabolic improvements suggests a more competitive efficacy profile and potential for expanded label indications.
- VKTX+0.60
No priced-in read yet





